Trial Profile
Impact of STK11/LKB1 mutations on the clinical outcomes of Chemo-immunotherapy (Pembrolizumab and chemotherapy) in patients with metastatic non-squamous Non small cell lung cancer
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 09 Oct 2018
Price :
$35
*
At a glance
- Drugs Pembrolizumab (Primary) ; Carboplatin; Pemetrexed
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- 09 Oct 2018 New trial record
- 26 Sep 2018 Results presented at the 19th World Conference on Lung Cancer